Home » SUNESIS PHARMACEUTICALS ANNOUNCES PRECLINICAL MILESTONE PAYMENT IN BACE COLLABORATION WITH MERCK
SUNESIS PHARMACEUTICALS ANNOUNCES PRECLINICAL MILESTONE PAYMENT IN BACE COLLABORATION WITH MERCK
Sunesis Pharmaceuticals, Inc. today announced that it has earned a $4.25 million payment from Merck & Co., Inc. for meeting certain
preclinical milestones in the companies' collaboration to develop oral small molecule inhibitors of beta-amyloid converting enzyme (BACE), which is believed to play a key role in Alzheimer's disease.
Yahoo
News
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May